Trial Profile

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; Olaparib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer; Non-small cell lung cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

08 May 2025 Planned End Date changed from 10 Apr 2025 to 10 Apr 2026.
11 Apr 2024 Planned End Date changed from 31 Dec 2023 to 10 Apr 2025.
11 Apr 2024 Status changed from discontinued to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com